Prévention de la paralysie cérébrale du grand prématuré par le sulfate de magnésium

Abstract

This review concentrates on the best evidence emerging in recent years on cerebral palsy prevention by administration of magnesium sulfate in mothers at risk of pre-term birth before 33-34 weeks' gestation. It was shown in the Cochrane database and in 3 meta-analyses of 5 randomized trials (Magpie Trial [neuroprotection of the pre-eclamptic mother], MagNet [neuroprotection/other intent: tocolysis], ActoMgSO(4) [neuroprotection], PreMag [neuroprotection], and Beam [neuroprotection]) that prenatal low-dose magnesium sulfate given to mothers at risk of pre-term birth has no severe deleterious effects in mothers and does not increase pediatric mortality in very pre-term infants. Moreover, it has significant neuroprotective effects on the occurrence of cerebral palsy at 2 years of age (relative risk, 0.69; 95% confidence interval, 0.54-0.87) and, in the neuroprotection subgroup, on the combined outcome of pediatric mortality or cerebral palsy (relative risk: 0.85; 95% confidence interval: 0.74-0.98). The number needed to treat (NTT) to prevent 1 case of cerebral palsy was 63 (95% CI, 39-172) and the NTT for an extra survivor free of cerebral palsy in the neuroprotection subgroup was 42 (95% CI, 22-357), justifying that magnesium sulfate should be discussed as a stand-alone treatment or as part of a combination treatment.